Eflornithine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Eflornithine: From African Trypanosomiasis/Hirsutism to Esotropia
One-Sentence Summary
Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor known for treating African trypanosomiasis (sleeping sickness) and topical hirsutism (Vaniqa). The TxGNN model predicts it may be effective for Esotropia, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph inference with no direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | African trypanosomiasis (systemic); topical hirsutism (Vaniqa) — no Taiwan marketing license on file |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Eflornithine works by irreversibly inhibiting ornithine decarboxylase (ODC), blocking polyamine synthesis. This mechanism underlies its approved uses — systemic treatment of African trypanosomiasis and topical suppression of facial hair growth (Vaniqa) — both of which depend on halting cell proliferation in parasites or hair follicles.
Esotropia (inward eye deviation) is a neuromuscular/ocular-alignment disorder typically managed with prism correction, botulinum toxin, or surgery. There is no known physiological link between the ODC/polyamine pathway and extraocular muscle tone or neural control of eye position. The high TxGNN score most likely reflects an indirect graph relationship (e.g., shared genes or co-occurring nodes) rather than a pharmacological rationale, and should be treated as a low-confidence signal requiring manual expert review.
For context, the evidence pack’s second-ranked candidate, neurotrophic keratopathy (score 99.38%), is arguably even less plausible: this condition requires promoting corneal epithelial repair, whereas eflornithine’s antiproliferative mechanism (blocking polyamine synthesis) would theoretically work against that goal. Both candidates illustrate the same limitation — model-only predictions without any mechanistic or clinical corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Eflornithine currently holds no marketing authorization in Taiwan (0 licenses on file; market status: 未上市).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but it is unsupported by any clinical trials, literature, or plausible mechanistic rationale, and a Blocking data gap (TFDA label warnings/contraindications) prevents even an initial safety assessment.
To proceed, the following is needed:
- TFDA/DrugBank-sourced labeling data (warnings, contraindications) to clear the current Blocking data gap
- Confirmed mechanism of action documentation to properly evaluate mechanistic plausibility for esotropia (and to resolve the apparent contradiction for neurotrophic keratopathy)
- Preclinical or observational evidence establishing any biological link between ODC/polyamine inhibition and either candidate indication before further evaluation is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.